NASDAQ$GYRE
Gyre Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Catalyst Biosciences reported its Q4 2021 operating and financial results, pivoting its strategy towards complement therapeutics and protease medicines.
Catalyst Biosciences reported a net loss of $20.3 million for Q4 2021. The company is focusing on complement therapeutics, including CB 2782-PEG and CB 4332, and is exploring strategic alternatives while implementing cost reduction measures.
- Regained rights to CB 2782-PEG for dry AMD treatment.
- Received Rare Pediatric Disease Designation for CB 4332 for CFI Deficiency.
- Announced plans to explore strategic alternatives for the company.
- Implemented personnel and cost reductions, including a 70% headcount reduction.
Headline financials
Revenue & EPS history
Gyre Therapeutics · Revenue · Quarterly
$2.44M
Revenue by segment
Gyre Therapeutics · $2.3M total across 1 segment · Q3 2021
- License & Collaboration$2.3M—100.0%
Forward guidance
Catalyst Biosciences is focused on developing protease therapeutics to address unmet medical needs in disorders of the complement system and is exploring strategic alternatives.
Tailwinds
- Potential strategic alternatives for the company
- Potential markets for CB 2782-PEG and CB 4332
- Plans for clinical development of CB 2782-PEG and CB 4332 in dry AMD
- Continued generation of candidates to treat diseases that result from dysregulation of the complement cascade
- Benefits of the protease engineering platform
Headwinds
- Risk that we will not identify or execute any strategic alternatives
- Clinical trials and preclinical studies may be delayed as a result of COVID-19, competitive products, and other factors
- CB 2782-PEG, CB 4332 and the Company’s complement degraders are not yet in human clinical trials and will require clinical additional testing, including multiple clinical trials, before being approved
- The Company will need to raise additional capital
- Other risks described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-0.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+8.5%
Avg return
30 days after
49%
23 / 47 earnings
Positive
+11.6%
Q3 2018
Best reaction
-43.2%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.8% | +2.8% | -11.2% | |
| Q4 2025 | +2.0% | -10.2% | -5.4% | |
| Q3 2025 | -1.6% | +13.6% | +8.7% | |
| Q1 2025 | +0.5% | +9.6% | -11.3% | |
| Q3 2024 | -13.6% | -21.2% | -39.8% | |
| Q2 2024 | -6.5% | +2.1% | +28.7% | |
| Q1 2024 | -5.5% | +0.5% | -29.3% | |
| Q4 2023 | +8.3% | +8.0% | +0.9% | |
| Q3 2023 | +0.0% | -15.3% | +144.2% | |
| Q2 2023 | +8.8% | +58.8% | +50.0% | |
| Q1 2023 | +5.0% | +5.0% | +5.0% | |
| Q4 2022 | +5.0% | +5.0% | +5.0% | |
| Q3 2022 | -1.8% | +0.0% | -12.5% | |
| Q2 2022 | -1.6% | +3.6% | +2.1% | |
| Q1 2022 | -24.5% | -26.5% | +173.5% | |
| Q4 2021 | +0.0% | -3.0% | -27.3% | |
| Q3 2021 | -43.2% | -51.0% | -62.9% | |
| Q2 2021 | +7.4% | +3.7% | +10.3% | |
| Q1 2021 | -2.4% | -5.4% | -9.5% | |
| Q3 2020 | +4.5% | +7.4% | +11.3% | |
| Q2 2020 | -0.6% | -2.0% | -13.5% | |
| Q1 2020 | +7.2% | -2.7% | +21.9% | |
| Q3 2019 | -3.1% | -6.1% | -8.7% | |
| Q2 2019 | +6.7% | -3.2% | -22.1% | |
| Q1 2019 | -5.3% | +2.7% | -9.2% | |
| Q3 2018 | +11.6% | +24.7% | +20.0% | |
| Q2 2018 | +6.6% | +6.6% | +11.9% | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | +1.2% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2014 | +3.7% | — | — | |
| Q4 2013 | -0.8% | — | — | |
| Q3 2013 | -5.4% | — | — | |
| Q2 2013 | -3.6% | — | — | |
| Q1 2013 | +0.5% | — | — | |
| Q4 2012 | -0.5% | — | — | |
| Q3 2012 | +0.7% | — | — | |
| Q2 2012 | -0.9% | — | — | |
| Q1 2011 | -2.7% | — | — | |
| Q1 2012 | +0.4% | — | — | |
| Q4 2011 | +0.1% | — | — | |
| Q4 2009 | +0.1% | — | — | |
| Q3 2010 | +3.9% | — | — | |
| Q3 2011 | +3.9% | — | — | |
| Q2 2010 | -1.4% | — | — | |
| Q2 2011 | -1.4% | — | — | |
| Q4 2010 | -1.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro